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Monthly intravenous pegylated liposomal doxorubicin (PLD) 50mgm
 2, although well tolerated, showed almost no activity in this
phase II study of 16 patients with advanced hepatocellular carcinoma with a response rate of 0%, stable disease 19%, median time to
progression of 2.4 months, 1-year survival of 25% and median survival of 6.5 months.
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Surgery, currently the only treatment offering long-term cure, is
possible in a minority of patients with hepatocellular carcinoma
(HCC) (Llovet et al, 2003). In selected patients with unresectable,
liver-only, disease hepatic embolisation or chemoembolisation
confers a survival advantage compared with conservative manage-
ment (Llovet et al, 2002; Lo et al, 2002). However, in the recent
meta-analysis, this effect may be limited to chemoembolisation but
not embolisation (Llovet and Bruix, 2003). Chemotherapy for
inoperable and extrahepatic disease is relatively ineffective; the
current ‘standard’, doxorubicin, has a response rate of 16% (range
0–35%) in a review of eight trials including 475 evaluable patients
(Engstrom et al, 1993). It is associated with a small survival
advantage over supportive care alone in a randomised study of 106
chemotherapy-naı ¨ve patients at the expense of significant toxicity
(mucositis, alopecia, myelosuppression and cardiotoxicity) (Lai
et al, 1988).
Liposomes, capable of encapsulating anticancer agents without
chemical modulation, accumulate preferentially in the reticulo-
endothelial system (Weinstein, 1984). This uptake may be evaded
by ‘stealth’ liposomes (formed by altering the liposome lipid
composition), which preferentially exit the circulation via leaky
capillaries and are predicted to accumulate in tumours exhibiting
extensive neo-vascularisation (such as HCC) leading to higher
concentrations and enhanced antitumour activity (Wu et al, 1993).
Pegylated liposomal doxorubicin (PLD), an intravenous prepara-
tion of doxorubicin hydrochloride encapsulated in long-acting
pegylated ‘stealth’ liposomes, can avoid rapid hepatic uptake
resulting in a prolonged circulation time. Compared to conven-
tional doxorubicin, intratumoural doxorubicin levels in tumour-
bearing mice were substantially higher when using PLD. Moreover,
enhanced cytotoxicity of an HCC cell line has been demonstrated
using ‘stealth’ liposomes compared to conventional doxorubicin
(Shimizu et al, 1996).
Dose-limiting toxicities of PLD include reversible neutropaenia,
stomatitis and plantar-palmar erythrodysaesthesia. Alopecia and
emesis are infrequent (Uziely et al, 1995). A phase I study in 33
patients with advanced HCC determined neutropaenia as the dose-
limiting toxicity at 60mgm
 2 and recommended 50mgm
 2 every
28 days as the phase II dosing regimen (Schering Plough – data on
file). Endomyocardial biopsies have shown PLD to have a superior
cardiac safety profile compared to nonliposomal doxorubicin
(Berry et al, 1998).
MATERIALS AND METHODS
Patient selection
An open-label, phase II study was performed. Chemotherapy-naı ¨ve
patients (including chemotherapy as part of chemoembolisation
procedures) with histologically proven HCC, aged X18 years, with
measurable disease by CT/MRI scan (WHO criteria), WHO
performance score (PS) of p2, life expectancy X3 months, left
ventricular ejection fraction (LVEF) X50% (by MUGA or
echocardiography), haemoglobin 49gdl
 1, white blood cells
X3.0 10
9l
 1, neutrophils X1.5 10
9l
 1 and platelets
X100000mm
 3, serum creatinine o1.5 upper limit of normal
(ULN), bilirubin o1.5 ULN and AST/ALT o2 ULN (unless
related to primary disease when value o5 ULN) were eligible.
Patients with New York Heart AssociationXClass II cardiac
disease, patients who were pregnant, lactating or were unwilling
to use contraception during the study were excluded. The
appropriate Local Research Ethics Committees at each institution
approved the study and all patients gave written informed consent
prior to study entry.
Treatment
Patients received PLD (Caelyx
s/Doxil
s, Schering-Plough head-
quarters, Kenilworth, NJ, USA) 50mgm
 2 in 250–500ml of 5%
dextrose i.v. over 1h on day 1 of each 28-day cycle. Retreatment
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soccurred upon recovery of platelets to X75000mm
 3, ANC to
X1.5 10
9l
 1 and skin toxicity or stomatitis to grade p1. A 25%
dose reduction was permitted for delayed recovery from toxicity or
grade X2 toxicity. Patients were withdrawn from the study for a
deferral of a treatment cycle (for toxicity) by more than 2 weeks.
Evaluation
Tumour assessments (CT/MRI scan) and cardiac assessments
(ECG/LVEF) were made at baseline and after cycles 3, 6 and 9.
Patients received PLD until disease progression, unacceptable
toxicity, patient choice or physician’s discretion. Toxicity (NCI-
Common Toxicity Criteria, version 2.0), vital signs and serum
biochemistry (including serum AFP) were assessed at baseline and
at every cycle with weekly blood counts during the study period.
All patients were followed up for survival data.
RESULTS
A total of 16 patients (see Table 1 for patient characteristics)
received a total of 47 cycles (median 3, range 1–9) at two
institutions (Christie Hospital, Manchester, UK (n¼13) and
University College Hospital, London, UK (n¼3)) between
November 1998 and April 2002.
Toxicity
Treatment was well tolerated with most toxicities reported at grade
1. Grade 3–4 toxicity included leucopaenia, neutropaenia, nausea/
vomiting and lethargy in 12, 12, 6 and 6% of patients, respectively
(and 4, 6, 2 and 2% of cycles, respectively). Dose delays were
required on three occasions and a total of three dose reductions
were made. One patient with persistent grade 4 neutropaenia was
withdrawn from treatment. No cardiac toxicity was observed.
Hepatic toxicity was mostly grade 1; grade 2 hyperbilirubinaemia
was seen in 27% of patients (9% of cycles) and elevated serum
alkaline phosphatase in 9% of patients (3% of cycles). No grade 2
transaminitis or grade 3–4 hepatotoxicity was documented
(Table 2).
Response and survival
No responses were seen in the first 16 patients and the study was
closed to accrual as the minimal threshold of activity had not been
reached according to the Simon one sample, two-stage design
(Simon, 1989). Three patients (19%) had stable disease after three
cycles, with disease progression in the remaining patients
(including the three patients with FLHCC). One of the three
patients with stable disease had ongoing stable disease after six and
nine cycles of treatment. The median time to disease progression
in all patients was 2.4 months with 1-year and 2-year survival rates
of 25 and 12.5%, respectively. The median survival of all patients
was 6.5 months. As expected, patients with FLHCC had a longer
median survival (20.5 months) than patients with standard HCC
histology (4.3 months).
Second-line chemotherapy was administered to six patients
(38%) (gemcitabine alone (n¼3) or with cisplatin (n¼3)). Two
patients receiving cisplatin–gemcitabine achieved disease stabili-
sation having previously progressed, the remainder had disease
progression. One patient with FLHCC achieved a sustained partial
response with continuous-infusion 5-FU and interferon having
failed PLD followed by cisplatin–gemcitabine and remains alive at
54 months.
Two patients (13%) with disease confined to the liver were
deemed suitable for chemoembolisation at first assessment. The
choice was made to proceed with PLD in the first instance (prior
chemoembolisation would have deemed them ineligible). Both
progressed after three cycles of PLD and then underwent
chemoembolisation (achieving survivals of 16 and 25 months,
respectively). Five patients (31%) received palliative hormone
therapy.
DISCUSSION
Doxorubicin, with modest activity, is a toxic agent and patients
with advanced HCC are frequently unwell due to their underlying
tumour and hepatic dysfunction. There was an expectation that its
efficacy could be maintained (or even enhanced) with the better
tolerated PLD formulation (Uziely et al, 1995).
A number of studies contemporary to ours (see Table 3) have
shown, at best, response rates of 10–17% (Ruff et al, 2001;
Schmidinger et al, 2001; Hong and Tseng, 2003). Two studies, as in
our case, revealed no responses: in the first, no objective responses
were seen in 16 patients receiving 30–40mgm
 2 three-weekly.
Table 1 Patient demographics
Characteristics Number (%)
Patients entered 16
Age (years)
Median (range) 56 (23–65)
Sex
Male 12 (75%)
Female 4 (25%)
Performance status at enrolment (WHO)
0 3 (19%)
1 13 (81%)
Tumour histology
Hepatocellular carcinoma 13 (81%)
Fibrolamellar type 3 (19%)
Tumour stage
4A 7 (44%)
4B 9 (56%)
Table 2 Reported toxicity by patient (n¼16) and by cycle (n¼47)
By patient By cycle
Toxicity/grade 1 2 3 4 1 2 3 4
Haemoglobin 63 13 0 0 47 6 0 0
WBC 13 6 6 6 13 6 2 2
Neutrophils 13 13 6 6 15 4 4 2
Platelets 25 0 0 0 17 2 0 0
Nausea/vomiting 63 6 6 0 45 2 2 0
Hepatic
Bilirubin 36 27 0 0 26 9 0 0
Alkaline phosphatase 27 9 0 0 32 3 0 0
AST 55 0 0 0 29 0 0 0
Diarrhoea 38 6 0 0 19 15 0 0
Lethargy 31 31 6 0 34 9 2 0
Cutaneous 25 0 0 0 28 0 0 0
Anorexia 19 6 0 0 11 2 0 0
Fever/sepsis 13 13 0 0 6 4 0 0
Mucositis 13 13 0 0 4 9 0 0
Alopecia 0 6 0 0 0 6 0 0
Constipation 0 6 0 0 0 2 0 0
Cardiac 0 0 0 0 0 0 0 0
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sWith a median survival of 20 weeks, the authors concluded that
PLD was ineffective (Halm et al, 2000). Miller et al (2002) reached
the same conclusion with a 0% response rate in a mixed study of
10 HCC (and eight cholangiocarcinoma) patients. Based on a
median survival of 1-year, Schmidinger et al (2001) concluded that
PLD warranted further studies. However, Ruff et al (2001) who
demonstrated a 17% response rate achieved a median survival of
only 5.3 months. The difficulty in relying on response rate as a
marker of activity was further illustrated by Hong and Tseng
(2003): despite 10% of patients responding to treatment and a
further 33% achieving stable disease, the median survival was only
3 months.
A favourable toxicity profile has been consistent across all the
HCC studies (Halm et al, 2000; Ruff et al, 2001; Schmidinger et al,
2001; Miller et al, 2002; Hong and Tseng, 2003). We found few
grade 3–4 toxicities and notably none involving palmar-plantar
erythrodysaesthesia, a dose-limiting toxicity seen in early studies
along with stomatitis and neutropaenia (Muggia et al, 1997;
Ranson et al, 1997). Cardiac toxicity was not seen and dose
reductions or dose delays due to toxicity were uncommon.
Enhanced activity of PLD was postulated by increased leakage
from capillaries in vascular tumours once the drug had evaded
rapid hepatic uptake. This reduced uptake may, however, also be
responsible for the lack of hepatotoxicity and, ultimately, efficacy.
Despite the ability to deliver doxorubicin more safely to
patients, PLD has almost no activity in advanced HCC. This
reflects the relative insensitivity of HCC to chemotherapy agents
and success may come from alternative treatment modalities
aimed at better targeting of the underlying pathological processes
involved in HCC carcinogenesis.
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